PRESSRELEASES

18 February, 2021

Nanexa Year-end report 2020

“The fourth quarter of 2020 was one of the most eventful in Nanexa’s history. We received a GMP certificate for drug manufacturing and a clinical trial permit for our NEX-18 project. We signed a collaboration agreement with Applied Materials and an investment agreement with Applied Ventures and, after careful evaluation, we decided shortly after the end of the quarter to choose lenalidomide for our NEX-20 project.” David Westberg, CEO Nanexa

18 February, 2021

Nanexa announces the result of the use of warrants of series TO2

Nanexa AB (”Nanexa” or ”the Company”) today announced the result of the use of warrants of series TO2, which were issued in connection with the Company’s rights issue in February 2020. The result shows that a total of 2,956,588 warrants were used to subscribe for 2,956,588 new shares in the Company, corresponding to approximately 97.5 percent of the total number of issued warrants of series TO2.

CURRENT



21 januari, 2021

Redeye Fight Cancer Seminar 2021

NEWSLETTER

Meet Nanexa

  • No scheduled meetings